ES2164434T3 - Tratamiento topico de psoriasis que utiliza anticuerpos neutralizantes de il-8. - Google Patents

Tratamiento topico de psoriasis que utiliza anticuerpos neutralizantes de il-8.

Info

Publication number
ES2164434T3
ES2164434T3 ES98930578T ES98930578T ES2164434T3 ES 2164434 T3 ES2164434 T3 ES 2164434T3 ES 98930578 T ES98930578 T ES 98930578T ES 98930578 T ES98930578 T ES 98930578T ES 2164434 T3 ES2164434 T3 ES 2164434T3
Authority
ES
Spain
Prior art keywords
psoriasis
neutralizing antibodies
topical treatment
biological activity
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98930578T
Other languages
English (en)
Inventor
George Q W Ye
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yes Biotech Laboratories Ltd
Original Assignee
Yes Biotech Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yes Biotech Laboratories Ltd filed Critical Yes Biotech Laboratories Ltd
Application granted granted Critical
Publication of ES2164434T3 publication Critical patent/ES2164434T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composición farmacéutica para administración tópica para el tratamiento de una enfermedad inflamatoria de la piel, que comprende un anticuerpo que neutraliza la interleucina-8.
ES98930578T 1997-06-23 1998-06-23 Tratamiento topico de psoriasis que utiliza anticuerpos neutralizantes de il-8. Expired - Lifetime ES2164434T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN97112184A CN1068524C (zh) 1997-06-23 1997-06-23 一种治疗顽症牛皮癣的药物

Publications (1)

Publication Number Publication Date
ES2164434T3 true ES2164434T3 (es) 2002-02-16

Family

ID=5172124

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98930578T Expired - Lifetime ES2164434T3 (es) 1997-06-23 1998-06-23 Tratamiento topico de psoriasis que utiliza anticuerpos neutralizantes de il-8.

Country Status (9)

Country Link
US (1) US20030077283A1 (es)
EP (1) EP0991423B1 (es)
CN (1) CN1068524C (es)
AT (1) ATE205401T1 (es)
AU (1) AU727937B2 (es)
CA (1) CA2291144C (es)
DE (1) DE69801660T2 (es)
ES (1) ES2164434T3 (es)
WO (1) WO1998058671A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068319A1 (en) * 2001-03-23 2003-04-10 Menashe Bar-Eli Methods for inhibition of angiogenesis, tumor growth and metastasis by fully human anti-IL8 and anti-MUC18 in diverse types of tumors
FR2830449B1 (fr) * 2001-10-05 2004-04-23 Fabre Pierre Dermo Cosmetique Utilisation du tazarotene pour la preparation d'un vernis a ongles pour le traitement et/ou la prevention du psoriasis et un vernis a ongles le contenant
US7282568B2 (en) 2002-12-16 2007-10-16 Medarex, Inc. Human monoclonal antibodies against interleukin 8 (IL-8)
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
WO2009041643A1 (ja) 2007-09-26 2009-04-02 Chugai Seiyaku Kabushiki Kaisha Cdrのアミノ酸置換により抗体の等電点を改変する方法
ES2661310T3 (es) * 2009-03-09 2018-03-28 Bioatla, Llc Proteínas mirac
EP4231014A3 (en) 2010-11-30 2024-03-20 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
US11236168B2 (en) 2012-08-24 2022-02-01 Chugai Seiyaku Kabushiki Kaisha Mouse FcγammaRII-specific Fc antibody
KR102318483B1 (ko) 2013-04-02 2021-10-27 추가이 세이야쿠 가부시키가이샤 Ｆｃ영역 개변체
CN105521489A (zh) * 2014-09-28 2016-04-27 徐州逸仕生物技术有限公司 抗人TNF-αIgY抗体及其治疗皮肤疾病的应用
MY181199A (en) 2014-12-19 2020-12-21 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
CN107108729A (zh) 2015-02-05 2017-08-29 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il‑8‑结合抗体，及其应用
RO130965A8 (ro) * 2015-10-16 2017-06-30 Romvac Company S.A. Producerea şi utilizarea oului hiperimun personalizat () în tratamentul psoriazisului
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
KR20230079499A (ko) 2016-08-05 2023-06-07 추가이 세이야쿠 가부시키가이샤 Il-8 관련 질환의 치료용 또는 예방용 조성물
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
JP2019535829A (ja) 2016-11-21 2019-12-12 エイリオン セラピューティクス， インコーポレイテッド 大型薬剤の経皮送達
EP3737696A1 (en) 2018-01-12 2020-11-18 Bristol-Myers Squibb Company Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
CN116327926A (zh) 2018-03-15 2023-06-27 中外制药株式会社 对寨卡病毒具有交叉反应性的抗登革热病毒抗体及使用方法
CN109481674A (zh) * 2018-11-14 2019-03-19 大连亚维药业有限公司 一种生物无菌乳膏药物的生产方法
WO2023192478A1 (en) 2022-04-01 2023-10-05 Bristol-Myers Squibb Company Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4364933A (en) * 1979-12-04 1982-12-21 Ortho Pharmaceutical Corporation Monoclonal antibody to a human thymocyte antigen and methods of preparing same
GB9009548D0 (en) * 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
US5440021A (en) * 1991-03-29 1995-08-08 Chuntharapai; Anan Antibodies to human IL-8 type B receptor
EP0563487A1 (en) * 1992-03-31 1993-10-06 Laboratoire Europeen De Biotechnologie S.A. Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon
US5707621A (en) * 1994-08-31 1998-01-13 Chugai Pharmaceutical Co., Ltd. Supression of nephritis-induced protein excretion by anti-IL-8
JPH08277299A (ja) * 1995-04-06 1996-10-22 Fujirebio Inc 抗ｉｌ−８抗体、抗ｉｌ−８モノクローナル抗体を産生するハイブリドーマ及び該抗体を用いたｉｌ−８の測定方法
AU739058B2 (en) * 1996-11-08 2001-10-04 Biogen Idec Inc. Identification of unique binding interactions between certain antibodies and the human B7.1 and B7.2 co-stimulatory antigens

Also Published As

Publication number Publication date
AU8096298A (en) 1999-01-04
ATE205401T1 (de) 2001-09-15
AU727937B2 (en) 2001-01-04
DE69801660T2 (de) 2002-06-06
CA2291144A1 (en) 1998-12-30
WO1998058671A1 (en) 1998-12-30
CA2291144C (en) 2001-07-03
CN1068524C (zh) 2001-07-18
EP0991423A1 (en) 2000-04-12
CN1203105A (zh) 1998-12-30
DE69801660D1 (de) 2001-10-18
US20030077283A1 (en) 2003-04-24
EP0991423B1 (en) 2001-09-12

Similar Documents

Publication Publication Date Title
ES2164434T3 (es) Tratamiento topico de psoriasis que utiliza anticuerpos neutralizantes de il-8.
DK0892638T3 (da) Liposombaseret, topisk vitamin D-præparat
DE69526344D1 (de) Stabilgelzusammensetzung zur topischen behandlung von hautkrankheiten
EA200100721A1 (ru) Производное габапентина для предупреждения и лечения висцеральной боли
ES2194989T3 (es) Composicion adminstrada por via oral, que comprende una toxina de zonula occludens y un agente que tiene una actividad biologica, y su utilizacion.
ES2231826T3 (es) Anticuerpos monoclonales anti-cd6 para el tratamiento y el diagnostico de la psoriasis.
MX9801596A (es) Composiciones aliviadoras del prurito, cosmeticas y farmaceuticas o ambas.
WO2001028491A3 (en) Method and composition for the treatment of dermatologic diseases
BR9305783A (pt) Processo para preparar grânulos dispersiveis em água e grânulos dispersíveis em água
ATE245452T1 (de) Hyaluronatlyase als penetrationsförderer in topischen mitteln
PT1173201E (pt) Metodo para o tratamento de fibrose utilizando um antagonista da subunidade alfa 4 de integrina
ES2180774T3 (es) La utilizacion de triacetato de glicerilo para el tratamiento de onicomicosis.
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
ITRM960364A0 (it) Agente attivo terapeutico per il trattamento di malattie degenerative neuronali.
DE69705110T2 (de) Topische pharmazeutische zusammensetzungen, welche heparin enthalten
PT1237562E (pt) Processo de preparacao de extractos de micania contendo micanolida e di-hidromicanolida e utilizacao no tratamento das doencas proliferativas
NO992674L (no) Konturen til et transdermalt terapeutisk system
ES2180750T3 (es) Conjugado de un principio activo, un polieter y, en caso dado, una proteina nativa no considerada como exogena.
EA199901061A1 (ru) Новые соли врс-пептидов с органопротективной активностью, способ их получения и их использование в терапии
MX9302419A (es) Derivados de acido tetronico, tiotetronico y tetramico.
NO20000376D0 (no) Transdermalt terapeutisk system for frigiving av virkestoff gjennom huden inn i en organisme og fremgangsmåte for påfoering på huden
ES2149448T3 (es) Agentes terapeuticos y analiticos.
BR0012006A (pt) Método para evitar inflamações, doenças autoimunes e crescimento de tumor, e, uso de substâncias que suprimem a ativação mediada por ltbr
AP9801416A0 (en) Method Of treating a plant disease.
MX9201705A (es) Derivados de isoxazolil imidazol, procedimiento para su preparacion y su aplicacion como medicamentos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 991423

Country of ref document: ES